Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

A Prospective, Multi-center, Single-arm, Open-label Phase II Clinical Study of Pirtobrutinib Combined With Sonrotoclax and Rituximab in Patients With Relapsed/Refractory High-risk Mantle Cell Lymphoma Previously Treated With a Covalent BTKi.

This single-arm, multicenter, open-label phase II study aims to evaluate the efficacy and safety of pirtobrutinib plus sonrotoclax and rituximab in adults with high-risk relapsed/refractory mantle cell lymphoma after failure of prior covalent BTK-inhibitor therapy. **Approximately 35 patients are planned to be enrolled**. Subjects will receive 28-day cycles of the triple-drug regimen. Participants achieving complete response with undetectable MRD at cycle 12 may stop treatment; others may continue up to 24 cycles. The primary endpoint is the CR-uMRD rate at cycle 12. Secondary endpoints include ORR, CRR, DOR, PFS, OS and safety. Exploratory biomarker and quality-of-life analyses will also be performed.

Studieoversikt

Detaljert beskrivelse

This is a prospective single-arm, multicenter, open-label phase II trial. **Approximately 35 adult patients with histologically-confirmed high-risk relapsed/refractory mantle cell lymphoma who progressed after covalent BTK-inhibitor-containing therapy are planned to be enrolled**. Eligible patients will receive pirtobrutinib 200 mg once-daily, sonrotoclax ramp-up to 320 mg once-daily, and rituximab 375 mg/m² on day 1 of each 28-day cycle. Patients with CR-uMRD after 12 cycles may discontinue study treatment; remaining patients can continue therapy for a maximum of 24 cycles. Tumor response, MRD and safety (CTCAE 5.0) will be assessed regularly. All patients will receive long-term survival follow-up after treatment. Biomarker and patient-reported quality-of-life assessments will be conducted as exploratory analyses.

Studietype

Intervensjonell

Registrering (Antatt)

35

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300060
        • Tianjin Medical University Cancer Insititute & Hospital
        • Ta kontakt med:
          • Huilai Zhang, PHD
          • Telefonnummer: 086-02223340123
          • E-post: zhlwgq@126.com

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.

  • 2.Age ≥ 18 years, male or female.

  • 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.

  • 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease.

  • 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.

  • 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  • 7.Adequate hematological function:

    1. Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
    2. Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
  • 8.Adequate hepatic function:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);
    2. Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
  • 9.Adequate renal function:

    1. Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);
    2. Serum creatinine ≤ 1.5 × ULN.
  • 10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

  • 11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.

  • 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).

  • 13.Estimated life expectancy > 3 months.

  • 14.Capable of providing written informed consent, and able to understand and comply with study requirements.

Exclusion Criteria:

  • 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease.

  • 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.

  • 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.

  • 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).

  • 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy).

  • 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:

    1. Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
    2. Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
  • 7. Clinically significant cardiovascular disease, including:

    1. Myocardial infarction within 6 months before screening;
    2. Unstable angina within 3 months before screening;
    3. Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    4. QTcF (Fridericia correction) > 480 msec;
    5. History of second-degree type-II or third-degree atrioventricular (AV) block;
    6. New York Heart Association (NYHA) class III or IV congestive heart failure.
  • 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention.

  • 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months.

  • 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug.

  • 11. Requiring ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day wash-out period.

  • 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose.

  • 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy.

  • 14. Known hypersensitivity to urate-lowering agents.

  • 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome.

  • 16. Pregnant or breastfeeding women.

  • 17. Known hypersensitivity to any of the study drugs.

  • 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide informed consent, or comply with study requirements.

  • 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Pirtobrutinib + Sonrotoclax + Rituximab Combination Therapy

Patients receive pirtobrutinib 200 mg once daily continuously, sonrotoclax dose-escalated to 320 mg once daily, plus rituximab 375 mg/m² on Day 1 of each 28-day cycle. Treatment may stop at Cycle 12 for patients achieving CR-uMRD, with a maximum treatment duration of 24 cycles.

200 mg oral once daily, continuous administration throughout the treatment cycle (28-day cycle)

Dose ramp-up within the first 4 weeks to the target dose of 320 mg oral once daily, continuous dosing.

375 mg/m² intravenous infusion administered on Day 1 of each 28-day treatment cycle.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of complete response with undetectable minimal residual disease (CR-uMRD) at Cycle 12
Tidsramme: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients with high-risk relapsed/refractory mantle cell lymphoma who achieve complete response (CR) with undetectable minimal residual disease (uMRD) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy. uMRD is defined as peripheral blood MRD <10-⁵ as measured by the clonoSEQ assay.

At the end of Cycle 12 (each cycle is 28 days)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate (ORR) at Cycle 12
Tidsramme: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients achieving complete response (CR) or partial response (PR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

At the end of Cycle 12 (each cycle is 28 days)
Complete Response Rate (CRR) at Cycle 12
Tidsramme: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients achieving complete response (CR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

At the end of Cycle 12 (each cycle is 28 days)
Duration of Response(DOR)
Tidsramme: From initial objective response until progression, death, or the end of study follow-up, maximum 36-months after treatment initiation

The length of time between the achievement of criteria for response to treatment (first documented complete or partial response) and the first documented relapse or progression.

From initial objective response until progression, death, or the end of study follow-up, maximum 36-months after treatment initiation
Progression-free survival (PFS)
Tidsramme: From first drug dose until progression, death, or end of study follow-up, maximum 36-months after treatment initiation

The time from the enrollment of a subject to the occurrence of (in any way) progression of disease or Death for any reason. patients with indeterminate recurrence or Death at the last follow-up, defined as the date of the last Investigation

From first drug dose until progression, death, or end of study follow-up, maximum 36-months after treatment initiation
Overall Survival (OS)
Tidsramme: From first drug dose until death or end of study follow-up, maximum 36-months after treatment initiation

Time from the first dose of study treatment to death from any cause. Patients still alive will be censored at the date last known to be alive or the end-of-study follow-up.

From first drug dose until death or end of study follow-up, maximum 36-months after treatment initiation
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: From the first dose of study treatment until 30 days after the last dose of study treatment

Adverse events (AEs) and serious adverse events (SAEs) will be monitored throughout the study based on physical examination findings and laboratory test results, and graded according to NCI-CTCAE Version 5.0.

From the first dose of study treatment until 30 days after the last dose of study treatment
MRD Conversion and Subsequent MRD Relapse Rate
Tidsramme: At the end of Cycle 12 (each cycle is 28 days), at the end of Cycle 24 (each cycle is 28 days)

Rate of MRD negativity and subsequent MRD relapse assessed by high-sensitivity flow cytometry.Rate of conversion to MRD negativity and subsequent MRD relapse, assessed by high-sensitivity flow cytometry.

At the end of Cycle 12 (each cycle is 28 days), at the end of Cycle 24 (each cycle is 28 days)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

8. desember 2026

Primær fullføring (Antatt)

8. desember 2028

Studiet fullført (Antatt)

8. desember 2030

Datoer for studieregistrering

Først innsendt

9. oktober 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere